IP-strategy for new medical device platform

Important results from the project

The aim of the project was to develop an IP-strategy including an action plan to safely market and sell the Qvicia Platform globally. As part of the project, and with the help of consulting services, a first version of the above has been established. The IP-strategy and action plan includes a description of how the company´s assets can be protected, and also how we can limit the company´s liabilities in connection with customers using the platform´s content. After implementation (which is outside the project scope), these are expected to enable broader marking and sales.

Expected long term effects

Based on how other companies have solved similar problems, we - together with consultants - have during the course of the project investigated how Qvicia can protect the company´s assets and limit the company´s liabilities in connection with customers using the platform´s content. The work has resulted in a first version of an IP-strategy and an action plan. With this as a basis, we can now (outside the project) continue the implementation work with the goal of having a sufficiently controllable IP situation to enable a broader launch during Q4 2019.

Approach and implementation

During the project, a first version of an IP-strategy and an action plan have been developed. The work during the project has involved a combination of internal and external resources (consulting services). This has been crucial for ensuring the right competences and being able to work in parallel with different approaches within the project. The IP-strategy and action plan that the project has resulted in provides a good basis for the implementation work we now intend to do (outside the project´s scope) with the aim that the pilot sales of licenses initiated during 2018 can be switched up.